Xeris Pharmaceuticals (NSDQ:XERS) announced today that it entered into an exclusive agreement with Tetris Pharma to commercialize Ogluo. Chicago-based Xeris designed Ogluo (Gvoke PFS and Gvoke HypoPen in the U.S.) to be a ready-to-use, pre-mixed, pre-measured glucagon injection for treating severe hypoglycemia in adults, adolescents and children two years of age and older with diabetes mellitus. Get the […]
Diabetes
FDA approves Nevro’s Senza system to treat chronic pain with diabetic neuropathy
Nevro (NYSE:NVRO) announced today that it received FDA approval for its Senza system for treating chronic pain associated with PDN. The Redwood City, Calif.-based company’s stock was up nearly 6%, to 152.54 per share, by afternoon trading today. Nevro’s Senza system’s approval is specific to Nevro’s 10 kHz stimulation. The company is touting that it […]
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring. Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion. That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward the […]
FDA clears Dexcom Partner Web APIs
Dexcom (NSDQ:DXCM) announced today that it received FDA clearance for its Dexcom Partner Web application programming interfaces (APIs). The San Diego–based company’s Dexcom Partner Web APIs enable invited third-party developers to integrate real-time continuous glucose monitoring (CGM) data into their digital health apps and devices. Get the full story at our sister site, Drug Delivery Business […]
Eli Lilly acquires glucose-sensing insulin developer Protomer Technologies
Eli Lilly (NYSE:LLY) announced today that it acquired peptide- and protein-engineering platform developer Protomer Technologies. The potential value of the transaction is over $1 billion, depending on the achievement of future development and commercial milestones. Pasadena, Calif.–based Protomer Technologies develops next-generation protein therapeutics designed to identify and synthesize molecules that can sense glucose or other endogenous […]
Glytec appoints chief medical officer
Cloud-based insulin management software developer Glytec announced today that it appointed Dr. Jordan Messler as chief medical officer. Messler’s responsibilities as the company’s CMO include spearheading continuous improvement initiatives for Glytec’s clinical strategy and product development. Get the full story at our sister site, Drug Delivery Business News.
BD announces two new directors for diabetes spinoff
BD (NYSE:BDX) announced today that it appointed David F. Melcher and Dr. Claire Pomeroy as directors of its diabetes spinoff. Franklin Lakes, N.J.-based BD previously announced the separation of its diabetes care business into an independent, publicly traded company called NewCo. Get the full story at our sister site, Drug Delivery Business News.
DarioHealth touts data for diabetes management platform
DarioHealth (NSDQ:DRIO) recently presented data supporting its artificial intelligence (AI)-powered diabetes management platform. New York-based Dario’s research examined users who were given access to a new product experience designed to drive better health habits and behaviors through its AI-driven personalization engine. Get the full story at our sister site, Drug Delivery Business News.
Walmart teams up with Novo Nordisk to launch private-brand analog insulin
Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin. Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The […]
Medtronic touts trial results for InPen smart insulin pen, extended infusion system
Medtronic (NYSE:MDT) today presented positive study results for its InPen smart insulin pen and its extended-wear infusion set. Fridley, Minn.-based Medtronic touted real-world clinical results comparing glycemic outcomes for 1,736 individuals before and after using the InPen smart insulin pen for 90 days with a continuous glucose monitor (CGM). Get the full story at our […]
Senseonics touts new next-gen Eversense CGM data
Senseonics (NYSE:SENS) today presented further positive data evaluating its next-generation Eversense continuous glucose monitoring system. Germantown, Md.–based Senseonics presented data from the Promise study at the American Diabetes Association Virtual 81st Annual Scientific Sessions. The data adds to positive results already presented by the company at the beginning of this month that demonstrated high levels […]
